Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
about
Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesPhase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance statusA retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).Endpoints in phase II trials for advanced non-small cell lung cancer.Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient.A retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer.Risks and benefits with bevacizumab: evidence and clinical implications.SLC19A1 pharmacogenomics summary.Pemetrexed disodium in ovarian cancer treatment.A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLCEfflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancerStage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible.Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy.HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer.Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatmentThymidylate synthase inhibitors for non-small cell lung cancer.Bevacizumab in non-small-cell lung cancer: a review.Bevacizumab: overview of the literature.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?The place of pemetrexed in the management of non-small-cell lung cancer patients.Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer.On the pharmacogenetics of non-small cell lung cancer treatment.Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis.Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.Successful treatment with pemetrexed, Carboplatin, and bevacizumab for platinum-resistant adenocarcinoma of the lung.Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations.A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis.Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients.[Application of Bevacizumab in Non-small Cell Lung Cancer].Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study
P2860
Q26745422-0B961453-69D1-4A13-ABC2-3E7C28BC6201Q33404543-102184A6-CAA5-4183-B815-F5D882BDD8A5Q33417324-9B55441E-7BB5-45A3-96E6-96FB85C6FCBCQ33431019-5355431F-80B1-4D67-A5B1-AB7711671E1DQ33557040-87E79EC0-9F0B-4582-BD48-21347AE84D32Q33632656-52DAC6DD-761E-4980-9817-BF8A915380CCQ33857726-B94624FA-AB17-4D35-991B-C2DB87EF6075Q33949406-51DAFF5B-26B5-455D-BF59-8B531F93D724Q34205753-1B507EB7-2D4B-4F9F-B5A9-5CAB5E3EB748Q34253505-F33AF667-103D-494A-B41B-9AAB7155AC3DQ34322552-D3588BA0-1AD3-4B3A-AA0B-4743242E0A17Q34854658-F7F931D4-C66E-4CFB-B82E-F5CA5EF06213Q35050210-FB1BC7DB-87CE-49D2-8301-01D217743AA2Q36043023-C30C3CD3-A63C-445A-9038-3D380487B2FDQ36356058-51964004-7D54-4808-AB12-A66870E98CCDQ36499068-41307CDA-967C-4620-943A-999CD4B698B9Q36774217-CBB9BC31-AE08-4835-97B5-E2A38313B338Q36822204-7C4F4CDF-50C0-4F36-92BF-C6552B20D863Q36886148-220E8CCA-8518-402B-8495-5E1C403245D9Q37929783-64FAFF64-E8B4-4E6D-B739-FA312A7E45DEQ37931886-62C01047-5520-47F3-B50E-2E3056FFB3C5Q38010797-D9BC85F5-0F3A-4E03-BE70-385B112CF955Q38030053-69168CFF-78DD-43F0-BC83-A87CBB37820BQ38087999-4509D900-C5B4-4B95-BA9A-B50A4ABBD753Q38132693-21C43A01-9A9D-4EC0-A185-E87E852820BAQ38366755-E585C76F-CE10-4204-8F4C-49A88F0F6A83Q38694947-3E42165A-3915-4664-8C5A-E6A0D579F558Q38845004-46A7C229-7ED3-47F2-9031-394B0EF1CCB4Q41962742-71A70ACE-069F-4C86-9BF0-3F56A49F3A45Q42222934-AC9FB6D3-CDC2-4892-AE64-74C3D9798604Q42961795-CEFB07ED-EB14-478C-A660-5EA21CD4A063Q47715888-96F2BBB6-962E-44A8-8312-61E793A38CEAQ50648690-0AADF1B0-2A1A-44B1-A8D3-9CCBFD040B81Q51492680-DEEDC28D-B3AB-4B85-894B-3BACBBAA3DA4Q52647706-1F802274-69FF-4083-97B1-7286A875874EQ53564503-BE1D0D53-DC52-4596-96F7-03A23ACC37C0Q55556494-233AC378-0967-43E8-BCED-296587ED1035Q58765953-476423B1-5D85-4617-ADA2-6F07D58379F2
P2860
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase II trial of pemetrexed p ...... r: NCCTG and SWOG study N0426.
@ast
Phase II trial of pemetrexed p ...... r: NCCTG and SWOG study N0426.
@en
type
label
Phase II trial of pemetrexed p ...... r: NCCTG and SWOG study N0426.
@ast
Phase II trial of pemetrexed p ...... r: NCCTG and SWOG study N0426.
@en
prefLabel
Phase II trial of pemetrexed p ...... r: NCCTG and SWOG study N0426.
@ast
Phase II trial of pemetrexed p ...... r: NCCTG and SWOG study N0426.
@en
P2093
P2860
P356
P1476
Phase II trial of pemetrexed p ...... r: NCCTG and SWOG study N0426.
@en
P2093
Alex A Adjei
Araba A Adjei
Grace K Dy
Julian R Molina
Katie L Allen Ziegler
Kendrith M Rowland
Philip J Stella
Ralph G Zinner
Steven E Schild
Sumithra J Mandrekar
P2860
P304
P356
10.1200/JCO.2009.23.6406
P407
P577
2009-10-19T00:00:00Z